Is Semaglutide Safe? The 2026 Evidence Review

Semaglutide is the most-studied GLP-1 medication, with extensive safety data from clinical trials and post-marketing surveillance. Most adverse events are GI and resolve within weeks. Specific contraindications apply. Compounded semaglutide adds pharmacy-quality considerations on top of the molecule's own safety profile.

Last updated May 1, 2026.

Advertising disclosure: GLP Insights is reader-supported. When you book a consultation or purchase through our partner links, we may earn a commission at no additional cost to you. This does not influence which providers or medications we discuss. Learn how this site is funded.

Talk to a Provider About Semaglutide

Licensed providers · All 50 states · No insurance required

✓ Updated monthly with FDA + clinical research ✓ Affiliate-supported, editorially independent ✓ Plain-English explanations of complex medical topics

Quick Summary

For most eligible adults, semaglutide is considered safe under medical supervision. The active molecule has been on the US market since 2017 with broad real-world use. Cardiovascular outcomes are favorable. Specific contraindications (MTC history, MEN-2, pancreatitis, pregnancy) are firm. Compounded semaglutide is generally considered comparable when sourced from accredited US compounding pharmacies; quality of compounding pharmacy matters.

Trial-Based Safety: STEP, SUSTAIN, SELECT

The STEP program tested semaglutide for weight management across multiple populations:

STEP-1: Adults with obesity, 68 weeks, semaglutide 2.4 mg. Discontinuation for adverse events 7.0% vs 3.1% placebo.
STEP-2: Adults with T2D and obesity. Similar safety pattern.
STEP-3: Intensive lifestyle plus semaglutide. Generally well-tolerated.
STEP-4: Discontinuation after 20 weeks — no increase in adverse events on continued treatment.
STEP-5: 104-week extension — sustained safety profile.

The SUSTAIN-6 trial (T2D, cardiovascular outcomes) demonstrated CV benefit. The SELECT trial extended this to non-diabetic obesity with established CV disease.

Common Side Effects

Nausea (15–45%, dose-dependent)
Diarrhea (8–15%)
Vomiting (5–25%)
Constipation (11–24%)
Abdominal pain
Fatigue, headache, dizziness in early weeks
Decreased appetite (often the desired effect)

Serious Adverse Events

Pancreatitis: Rare (0.1–0.4%); symptoms warrant immediate evaluation.
Gallbladder disease: Slightly increased risk above placebo, related to rapid weight loss.
Severe hypoglycemia: Mainly in combination with insulin or sulfonylureas.
Acute kidney injury: Usually secondary to dehydration.
Anaphylaxis/angioedema: Rare.
Diabetic retinopathy worsening: Transient, in patients with pre-existing disease.

FDA Boxed Warning Reminder

All semaglutide products carry the boxed warning for thyroid C-cell tumors. Contraindicated in MTC or MEN-2 personal/family history.

Brand vs Compounded Semaglutide: Safety Considerations

The active molecule is the same. Differences:

Brand: FDA-approved manufacturing oversight; consistent formulation; pen delivery with metered dose.
Compounded: State-licensed pharmacy oversight, accreditation (PCAB, USP <797>) where available; vial + syringe format; quality depends on the pharmacy's sourcing and procedures.

Use compounded semaglutide only from accredited US compounding pharmacies through licensed telehealth prescribers. Avoid "research only," international imports, and non-prescription sources.

Pregnancy and Breastfeeding

Semaglutide is not recommended in pregnancy. Discontinue at least 2 months before planned conception. Animal studies have shown adverse developmental outcomes. Adequate human data are lacking. Effects on breast milk are unknown; avoid in breastfeeding unless cleared by your provider.

Talk About Whether Semaglutide Is Right

Licensed providers · All 50 states · No insurance required

Drug Interactions

Insulin and sulfonylureas: hypoglycemia risk; dose adjustments needed
Oral medications: delayed absorption due to slowed gastric emptying — important for narrow-therapeutic-index drugs
Levothyroxine, warfarin: monitor INR or TSH after starting

Long-Term Use

No established maximum duration of treatment. Most patients regain weight after stopping. Continued therapy is comparable to other chronic disease medications.

Special Populations

Older adults: Generally well-tolerated; watch hydration.
Kidney disease: No specific dose adjustment.
Liver disease: Caution in severe hepatic impairment.
Pediatric: Wegovy approved for adolescents 12+.

Counterfeit and Imported Semaglutide

The FDA has issued warnings about counterfeit semaglutide and unsafe imports. Risks include incorrect dosing, contamination, and absence of the active ingredient. Only use US-licensed pharmacy products with valid US prescription.

Frequently Asked Questions

Is semaglutide safe for weight loss? +

Semaglutide at 2.4 mg weekly (Wegovy) is FDA-approved for weight management in eligible adults. Clinical trial safety profile is well characterized; serious adverse events are uncommon but possible.

Is compounded semaglutide as safe as brand? +

When produced by an accredited compounding pharmacy with verified active pharmaceutical ingredient, compounded semaglutide is generally considered comparable in safety to brand semaglutide. Avoid any non-pharmacy or non-prescription sources.

Can I take semaglutide while pregnant? +

No. Semaglutide is not recommended in pregnancy and should be discontinued at least 2 months before a planned pregnancy.

Are there drug interactions to know? +

Semaglutide slows stomach emptying, which can affect oral medication absorption. Combination with insulin or sulfonylureas increases hypoglycemia risk. Review your full medication list with your provider.

Sources

FDA prescribing information for Ozempic, Wegovy, Rybelsus.
STEP-1 through STEP-5 publications.
SUSTAIN-6, SELECT trial publications.